Following a roadshow with institutional investors via several virtual conferences, Cheplapharm has priced €575 million of its 4.375% senior secured notes due 2028 and $500 million of its 5.500% senior secured notes due 2028 (the “Notes”). The final orderbook was multiple times oversubscribed.
Cheplapharm intends to use the proceeds from the Notes offering towards paying the purchase price for several marketing authorizations for certain medicinal products it agreed to acquire between June and September 2020 and costs and expenses related to the foregoing.
“I am very proud of the massive response we have received from investors in Europe and the United States.” states Sebastian F. Braun (CEO) after the pricing of the Notes.
“This transaction ensures that we are able to make a huge step forward in achieving our ambitious goals for this year. Our banks and lawyers did a great job during this transaction” added Jens Rothstein (CFO).
The Dollar tranche ensures an even higher flexibility for Cheplapharm’s business activities and shows Cheplapharm’s commitment to further optimizing, diversifiying and sustainably securing its long-term debt structure. The new financing structure offers Cheplapharm increased flexibility at attractive conditions.